Capital Cell Review 2026: Biotech Crowdfunding Fees, Exits and Investor Returns
Capital Cell is a Barcelona equity crowdfunding platform for early-stage biotech and medical companies, licensed by Spain's CNMV under the EU crowdfunding regulation and open across 26 other EU states from about EUR 500 a ticket. Its public track record lists 156 rounds since April 2016 (EUR 157.1 million of round size, including lead investors): 138 'In business', 14 'Write-off' and 4 'Exit' at three companies, with exit proceeds not published. Its own analysis of the 2015 to 2022 portfolio put reported value at 3.19x invested capital on paper, 1.14x without its three best investments, and cash returned as of November 2022 at 0.51.
No platform response on record for this review. Is this your platform? Respond or claim it.
What the data actually shows - TL;DR
Capital Cell, founded in Barcelona in 2015 by biologist Daniel Oliver Uriel, lets individuals buy into early-stage life-science companies (medical devices, biotech, new drugs, digital health, diagnostics) alongside a lead investor who sets the price. It is run by PFP CAPITAL CELL, S.L., authorized by Spain's CNMV as European crowdfunding service provider no. 12 since November 10, 2023, and notified to offer its service in the 26 other EU states; tickets start around EUR 500, money waits with a payment institution (MarketPay) until the company's capital increase is registered, and crowd investors usually hold through a Dutch STAK foundation.
Read the full assessmentShow less
The platform publishes more of its record than most: every round since 2017 with a status label, a register of related-party investments and an analysis that states its own realized return. That record is young and lopsided: 156 rounds, 14 labelled written off and 4 labelled exits at three companies (Vytrus Biotech's market listing, Goodgut's sale to Hipra, and two Bionure rounds; Bionure merged with Iproteos in 2020 to form Accure Therapeutics), with no published figure for what investors received from any exit. Capital Cell's analysis of its 2015 to 2022 portfolio, a different cohort from today's track-record table, reported a portfolio value of 3.19x invested capital, 1.14x without its three best investments, and cash returned of 0.51 as of November 2022.
Published fee rates differ by page: the company's success fee is 8% in the promoter conditions and terms but 7% in the investor FAQ, and investors holding through the STAK pay 8% of any profit at exit and 8% on early transfers. One register discrepancy needs an answer: the CNMV still lists the operator's sole owner as Capital Cell Ltd, a UK company that Companies House shows dissolved in June 2025 after a members' voluntary liquidation.
The track record lists 156 rounds from April 2016 to October 2026, EUR 157.1 million of round size (which includes lead and co-investors, not only crowd money). By year: 1 (2016), 5 (2017), 5, 14, 14, 16, 19, 19, 21, 25 and 17 (2026 to October). The home page says '175 Closed Rounds' and '168M€ Total Invested'; the difference is not explained (Capital Cell UK rounds, for example, are not on the list).
Labelled exits: four rounds at three companies. Vytrus Biotech (October 2017 round; listed on Spain's BME Growth market in 2022), Bionure (March 2017, EUR 477,000, and July 2019; Bionure merged with Iproteos in 2020 to form Accure Therapeutics) and Goodgut (2019; sold to Hipra). Labelled write-offs: 14 rounds, EUR 8.0 million of round size, including Frontwave Imaging twice, RUTI Immune (EUR 1.6 million), HCS Pharma and Exheus.
Of the 39 rounds from 2016 to 2020, 8 are written off, 4 are labelled exit and 27 are still 'In business'. Exit proceeds are not published.
Capital Cell's analysis of its 2015 to 2022 portfolio (78 companies, a different cohort from today's track-record table): reported value 'X3.19' of invested capital, mostly paper gains from later rounds; 'if we remove the 3 investments with the greatest revaluation, the portfolio return goes from X3.19 to only X1.14' (Spanish edition); and 'the cash return as of November 2022 is only 0.51'. The home page now shows '2,7x' portfolio value, not updated with a cash figure.
Company side: EUR 1,500 at campaign activation and a cash success fee of 8% (EUR 10,000 minimum) in the promoter conditions, terms and company FAQ; the investor FAQ says 7%. Investor side: through the STAK, 8% of profit at exit and 8% on transfers before exit; the how-to-invest page calls it 'an 8% carried interest'. The conditions apply 'unless expressly agreed', so check the terms of each round.
PFP CAPITAL CELL, S.L. (NIF B65998288) is an authorized crowdfunding service provider under Regulation (EU) 2020/1503 since November 10, 2023, with cross-border notifications for 26 EU states. A register discrepancy: the CNMV's partner view still shows 'CAPITAL CELL, LTD 100.00%', while Companies House records that UK company's members' voluntary liquidation (resolution July 2024) and dissolution on June 17, 2025. No sanction or warning was located.
Related-party investments disclosed under the EU regulation: 106 entries in 70 projects by partners (EUR 364,765), other related parties (EUR 225,030) and employees (EUR 49,651), including in companies later written off.
Round counts, sizes and status labels are Capital Cell's track-record pages as captured November 9, 2026 (recounted November 10); round size includes lead investors. Return multiples are Capital Cell's own analysis (paper values from later round prices). Write-offs and exits are not checked against company registries. Amounts in euros.
Visual Summary
Capital Cell rounds by year
From capitalcell.com/en/track-record as captured November 9, 2026; round size in euros includes lead investors; statuses are the platform's labels.
2016
1 round, EUR 0.29M (Cebiotex)
2017
5 rounds, EUR 2.07M; 2 exits (Bionure, Vytrus Biotech), 1 write-off
2018
5 rounds, EUR 3.62M; 2 write-offs
2019
14 rounds, EUR 11.71M; 2 exits (Bionure, Goodgut), 3 write-offs
2020
14 rounds, EUR 13.52M; 2 write-offs
2021
16 rounds, EUR 17.63M; 2 write-offs
2022
19 rounds, EUR 15.30M; 3 write-offs
2023
19 rounds, EUR 20.37M; 1 write-off
2024
21 rounds, EUR 18.57M
2025
25 rounds, EUR 31.53M
2026 (to October)
17 rounds, EUR 22.51M; 3 more campaigns open on November 9
Quick Verdict
Is this platform right for you?
Capital Cell is a regulated, specialist venture platform that shows more of its record than most: every round with a status, a related-party ledger, and its own report that the 2015 to 2022 portfolio was valued at 3.19x on paper while cash returned stood at 0.51 in November 2022. The record is young, with 4 exit labels at 3 companies in ten years and 14 write-offs, and the realized proceeds are not published.
Read the full assessmentShow less
Fees take 8% of investor profit at exit, and the published company rate is 8% in the terms but 7% in the investor FAQ. Before investing, read the round's own fee terms, ask who owns the operator given the register discrepancy over its dissolved UK parent, and treat the 2.7x on the home page as paper value.
Best for
- EU investors building a long-horizon, diversified set of life-science startup stakes
- Investors who want to follow lead investors' pricing
Avoid if
- You need liquidity or income
- You are a US retail investor
- You expect realized returns soon
Top strengths
- CNMV-authorized EU crowdfunding provider, passported to 26 states
- Full public round list with write-off and exit labels
- Related-party investment ledger and audited operator accounts (behind login)
- The platform's own cash-return figure published alongside paper multiples
- Lead investor sets the price in every round; all-or-nothing escrow at a payment institution
Key limitations
- 4 exit labels at 3 companies since 2016, proceeds not published
- 14 write-offs by the platform's labels, not registry-checked
- 8% of profit at exit and 8% on early transfers; published company fee rates conflict (8% vs 7%)
- Register discrepancy: CNMV still lists a UK owner dissolved in 2025
- Headline figures (175 rounds, EUR 168M, 2.7x) do not reconcile with the 156-round track record
Compare Before Deciding
Where Capital Cell fits against alternatives
Use these hooks to pressure-test whether this is the right platform, or whether a nearby alternative matches the job better.
How this compares to BioTech Funding Portal
BioTech Funding Portal
A US Reg CF portal for life sciences, with no offering filed yet.
How this compares to OurCrowd
OurCrowd
A venture platform with a large health portfolio and funds as well as single deals.
How this compares to VitaDAO
VitaDAO
Token-governed funding of longevity research.
156
Rounds on the track record
April 2016 to October 2026; EUR 157.1M round size including leads.
4 / 14
Exits / write-offs
Platform labels; the 4 exits are at 3 companies; proceeds not published.
3.19x / 0.51
Reported value / cash returned, November 2022
Capital Cell's 2015 to 2022 portfolio; 1.14x on paper without the top three.
8% / 8%
Company success fee / investor share of profit
Investor FAQ says 7% for the company; investors also pay 8% on transfers before exit.
Quick Answers
What most investors want to know first
The highest-signal facts first: minimums, liquidity reality, K-1 timing, and whether distributions are actually part of the experience.
Liquidity
Direct negotiation between users; no order book.
K-1 Timing
Not applicable (no US partnership).
Distributions
Only at exit.
Overview
Platform Overview
A concise read on what the platform is, how the structure works, and where the practical friction shows up for real investors.
Capital Cell screens early-stage health companies, pairs each with a 'reference investor' (a fund, business angel or corporate) who sets the round's price, and opens the rest of the round to registered investors on capitalcell.com. Campaigns are all-or-nothing: commitments are held by MarketPay, a payment institution, until the round closes and the capital increase is registered before a notary, with a 7-day reflection period. Crowd investors usually hold through a STAK, a Dutch foundation that is the legal shareholder and issues certificates, which keeps the company's register short and lets certificates change hands without a notary.
Investments start around EUR 500 ('under 1,000 EUR most of the time'). Under the EU regulation, non-sophisticated investors pass an entry knowledge test before getting full access, and above the higher of EUR 1,000 or 5% of their net worth per project they receive a risk warning and must explicitly acknowledge it. Investors from any country not on the EU tax-haven list can register; the FAQ says US and Japanese investors 'must provide proof of accreditation as professional investors'. Most rounds are Spanish companies, with a growing share from France and Italy.
An EU-licensed equity crowdfunding platform for early-stage life-science companies, with 156 rounds since 2016, 14 written off and 4 labelled exit at three companies, and an unusually frank analysis of its 2015 to 2022 portfolio: 3.19x reported value on paper, 0.51 returned in cash as of November 2022.
Company and people
PFP CAPITAL CELL, S.L., Barcelona (NIF B65998288; LEI 9598002AZWLHC7NUHX82); founder and sole director Daniel Oliver Uriel. CNMV still lists Capital Cell Ltd (UK; dissolved June 2025 after a members' voluntary liquidation) as 100% owner.
Regulation
CNMV-authorized crowdfunding service provider no. 12 under Regulation (EU) 2020/1503 since November 10, 2023; notified for 26 EU states. Not SEC-registered; US investors must prove professional status.
Investing
Equity in early-stage companies alongside a lead investor; usually through a Dutch STAK; from about EUR 500; non-sophisticated investors pass an entry knowledge test, with a risk warning above the higher of EUR 1,000 or 5% of net worth; all-or-nothing rounds with funds at MarketPay.
Fees
Company: EUR 1,500 at activation and an 8% cash success fee (EUR 10,000 minimum) per the promoter conditions; the investor FAQ says 7%. Investors: 8% of profit at exit and 8% on transfers before exit through the STAK; no annual fee. Round terms govern.
Track record
156 rounds (April 2016 to October 2026), EUR 157.1M round size incl. leads; 138 in business, 14 write-off, 4 exit at three companies (platform labels).
Court and enforcement record
No sanction, warning or dispute located (web searches; CNMV sanctions register not queried directly).
ASWhat the track record and filings show
- 156 rounds, most since 2023; too young for most outcomes.
- 2016 to 2020: 39 rounds, 8 written off, 4 exit labels at three companies.
- Reported value 3.19x and cash returned 0.51 for the 2015 to 2022 portfolio (November 2022).
Key Gaps & Non-Disclosures
- Exit proceeds to investors not published.
- Operator ownership after the UK parent's dissolution.
- Audited accounts behind login; published fee rates conflict (8% vs 7%).
Platform Intelligence
Capital Cell timeline
Key platform events, regulatory turns, liquidity stress points, and product launches that shape how the review should be read.
Founded
Daniel Oliver Uriel starts Capital Cell in Barcelona.
UK company formed; first listed round
Capital Cell Ltd incorporated in the UK (May); Spanish platform authorization reported. April: Cebiotex, the earliest round on the track record (EUR 286,000).
Bionure and Vytrus rounds
Five rounds on the track record, including Bionure (March) and Vytrus Biotech (October), both later labelled exit.
Bionure becomes Accure
Bionure merges with Iproteos to form Accure Therapeutics; the track record gives no crowd-investor payout.
Vytrus lists; portfolio analysis
Vytrus Biotech lists on BME Growth. November: Capital Cell's analysis of its 2015 to 2022 portfolio reports 3.19x value on paper and 0.51 returned in cash.
EU license
November 10: CNMV authorizes PFP CAPITAL CELL, S.L. as crowdfunding service provider no. 12, with notifications for 26 EU states.
UK parent wound up; 21 rounds
July: Capital Cell Ltd resolves on a members' voluntary liquidation. 21 rounds reach target; EUR 13M from 4,050 crowd investors.
UK parent dissolved; 25 rounds
June 17: Capital Cell Ltd dissolved, still shown at the CNMV as 100% owner. 25 rounds, EUR 31.5M round size.
17 rounds to October
17 rounds by October; Nanogrow Biotech, e-miRgency and fetaLife open on November 9.
Investor Operations
The practical questions investors actually care about: when tax documents arrive, how cash distributions work, and whether capital can be exited before the underlying asset is sold.
Tax Documents
K-1 Timing
What to expect
Not applicable (no US partnership).
Extension risk
Not stated.
Confidence: Low
Cash Flow
Distributions
Timing
Only at exit.
Consistency
4 exit labels at 3 companies since 2016.
Liquidity
Exit Reality
Holding period
Until an exit; typical early-stage horizons are many years.
Exit options
- Company sale or market listing
- Bulletin-board sale to another user (8% fee on STAK transfers before exit)
Secondary market
Direct negotiation between users; no order book.
Confidence: Medium
Investment Structures
Equity round via STAK (EU crowdfunding regulation)
Depositary certificates of a Dutch STAK holding shares issued by one early-stage life-science company in a capital increase led by a reference investor; from about EUR 500; all-or-nothing with funds at MarketPay until registration; 7-day reflection period; no annual fee, 8% of profit at exit and 8% on transfers before exit; resale through a bulletin board.
Risk
Risk Structure
This is where the marketplace pitch gives way to the actual operating reality: delayed exits, limited disclosure, fee drag, and path-dependent outcomes.
Early-stage life-science risk
Most rounds fund companies years from revenue or approval; the platform's own FAQ says 1 in 4 succeeds.
Few realized outcomes
4 exit labels at 3 companies in ten years, proceeds unpublished; cash returned 0.51 for the 2015 to 2022 portfolio at November 2022.
Illiquidity
Bulletin-board resale only, with an 8% fee on STAK transfers before exit.
Operator ownership
Register discrepancy: the CNMV still names a UK company dissolved in 2025 as sole owner.
Most outcomes are still ahead
82 of 156 rounds date from 2023 or later; 4 rounds at 3 companies are labelled exit.
Why it matters
The paper multiple will move with each company's next round; the realized record is thin.
Mitigation / verification
Ask for current cash-on-cash returns by vintage and the proceeds from each exit.
Fees on the upside and on early exits
8% of profit at exit and 8% on early transfers through the STAK; published company rates differ (8% or 7%), and the terms reserve a right to add fees.
Why it matters
Fees reduce what reaches investors in the few winners that carry a venture portfolio.
Mitigation / verification
Read the STAK terms and the fee section of the round's key investment information sheet before investing.
Who stands behind the operator
The CNMV register still names as sole owner a UK company dissolved in 2025.
Why it matters
Ownership affects the platform's continuity and the STAK's administration over a long holding period.
Mitigation / verification
Ask Capital Cell and check the CNMV register for an updated partner entry.
Biggest Misconceptions & What Actually Happens
- 'Portfolio Value 2,7x': paper value from later round prices, not cash returned.
- 'Total Invested 168M€': includes lead and co-investors, not only crowd money.
- 'Write-off' and 'In business': the platform's labels, not registry findings.
- 'Exit': includes a market listing (Vytrus), where investors' results depend on when they sold, and Bionure's merger into Accure Therapeutics.
- '7% per project' (investor FAQ): the terms, promoter conditions and company FAQ say 8%.
- 'Same conditions as professional investors': the share price is the lead's; other rights depend on each round.
Regulatory & Legal Posture
Security Status
Transferable securities (shares, through STAK certificates) offered by a European crowdfunding service provider under Regulation (EU) 2020/1503.
PFP CAPITAL CELL, S.L. is authorized by the CNMV as provider no. 12 since November 10, 2023, with cross-border notifications for 26 EU states. Offers to non-sophisticated investors carry the regulation's key investment information sheet, knowledge test and reflection period.
Disclosure Quality
Key investment information per round for registered users; a public track record and related-party ledger; audited operator accounts behind login.
Custody Model
Commitments held by MarketPay (payment institution) until the capital increase is registered; shares usually held by a Dutch STAK for certificate holders.
Regulatory Backing
CNMV supervision of the provider; MarketPay as a regulated payment institution.
Tax Treatment
Reporting
Country-specific; no US tax forms described.
Not stated.
Income Character
Capital gain or loss on exit.
Investors hold equity (through STAK certificates); Spanish residents may claim startup-investment deductions.
Limitation
US persons holding a Dutch STAK certificate in a foreign company should check PFIC and foreign-reporting rules with a tax adviser.
Account Suitability
Taxable
Yes.
Roth IRA
Not described.
Traditional IRA
Not described.
HSA
No.
Before You Invest
Get Capital Cell investor insights before you invest
K-1 timing, distribution updates, yield insights, and risk signals for Capital Cell and similar platforms.
- Weekly platform research focused on tax timing and liquidity reality.
- Signals on distributions, risks, and structural tradeoffs before capital is locked up.
- Coverage of adjacent platforms so you can compare better options faster.
Get weekly platform signals
Track fee changes, liquidity updates, risk flags, and adjacent platforms before you invest.
Independent intelligence from AltStreet. No hype. No sponsor spin.
AltStreet Data Layer
What the data actually shows
AltStreet parsed all 156 rounds on Capital Cell's track record, read its portfolio analyses, fee and STAK terms and related-party ledger, and checked the CNMV and UK registers.
Early vintages: 8 of 39 written off
Of the 39 rounds from 2016 to 2020, 8 are labelled write-off, 4 exit (at 3 companies) and 27 in business.
What this means
Most early companies are still private and unrealized six to ten years on.
Reported 3.19x, cash 0.51
Capital Cell's analysis of its 2015 to 2022 portfolio (November 2022); 1.14x on paper without the three best investments.
What this means
Returns are concentrated and mostly unrealized.
Register discrepancy on ownership
CNMV still lists Capital Cell Ltd as 100% owner; Companies House records its members' voluntary liquidation and dissolution on June 17, 2025.
What this means
Ask who owns the Spanish operator today.
Data as of 2026-11-10 . AltStreet review evidence layer . Public-source analysis
Full dataset156
Rounds on the track record
April 2016 to October 2026; EUR 157.1M round size including leads.
4 / 14
Exits / write-offs
Platform labels; the 4 exits are at 3 companies; proceeds not published.
3.19x / 0.51
Reported value / cash returned, November 2022
Capital Cell's 2015 to 2022 portfolio; 1.14x on paper without the top three.
8% / 8%
Company success fee / investor share of profit
Investor FAQ says 7% for the company; investors also pay 8% on transfers before exit.
Decision Fit
Investor Fit
Who this works for, who it does not, and what level of patience and complexity tolerance the platform really demands.
EU investors who want a spread of small, long-term biotech and medtech stakes alongside lead investors
Specialist deal flow, a public round list and low minimums; expect many years and several losses for each winner.
US investors
Must prove professional status; STAK certificates in EU companies bring tax complexity.
Investors who need liquidity or income
No distributions before exit and a bulletin-board secondary market.
Tradeoffs
Key Tradeoffs
The attraction of pre-IPO access is real, but every benefit comes bundled with a corresponding liquidity, transparency, or pricing cost.
Transparency vs. realized record
A full round list and a candid cash-return figure, but exits at only three companies in ten years.
Low minimum vs. venture odds
EUR 500 tickets into companies where, by the platform's own estimate, one in four succeeds.
No upfront fee vs. profit share
Investors pay at exit: 8% of profit, and 8% on any early transfer; check the round's own terms.
Avoid
Who This Is Not For
This section should be read as a filter, not an afterthought. If you need income, simplicity, or near-term access to capital, the structure is working against you.
Investors needing liquidity or income
Equity with no distributions and a bulletin-board secondary market.
US retail investors
Professional status required; foreign tax complexity.
Investors who want realized returns soon
Most rounds are from 2023 or later.
Editorial View
AltStreet Perspective
The compressed version of the review: what matters, what marketing tends to obscure, and how we would frame the platform for a serious allocator.
Verdict
A regulated, unusually transparent EU biotech crowdfunding platform whose realized record is still thin.
Positioning
Use it for a diversified, long-horizon set of small stakes; ask about ownership and exit proceeds first.
The Bottom Line
156 biotech rounds, exits at 3 companies, and a reported 3.19x portfolio value beside 0.51 returned in cash (November 2022).
Action
Next Steps
If you still want to engage after reading the review, these are the practical next moves that reduce avoidable mistakes.
Ask Capital Cell who owns PFP CAPITAL CELL, S.L.
today, given the CNMV and Companies House records disagree.
Ask for exit proceeds per company and a current cash-on-cash return by vintage.
Read the STAK terms, the round's key investment information sheet and the lead investor's terms before committing.
AltStreet Research Desk
About to invest in Capital Cell, or in an offering we haven't covered?
Commission an independent diligence report: the same filing-based analysis behind this review, applied to the specific investment in front of you before you wire the money.
- Built from primary sources: SEC filings, court records, capital structure, and marketing-versus-filings comparison.
- From $750; full reports from $1,495. Fixed price confirmed up front, delivery in 3-5 business days.
- Independent by design: we work for investors and accept no compensation from the companies we cover.
Want this on every new deal, not one? Deal Intelligence sends the alert the day a new offering appears on a covered platform and follows with an analyst-approved investment committee memo.
Deal Intelligence →Appendix
Sources, Disclosures, and Supporting Context
The lower section is structured like a report appendix: relationship context first, adjacent reading second, and evidence last.
Report Appendix
Disclosure
Relationship and compensation context
+
Report Appendix
Disclosure
Relationship and compensation context
Report Appendix
Related Resources
Adjacent platform comparisons, frameworks, and category links
+
Report Appendix
Related Resources
Adjacent platform comparisons, frameworks, and category links
Further Reading
Related Resources
Adjacent frameworks and reviews that help place the platform in a broader allocation or due-diligence context.
Explore Asset Class
Biotech / Early-Stage Life Science EquitySimilar Platform Reviews
- BioTech Funding Portal
A US Reg CF portal for life sciences, with no offering filed yet.
- OurCrowd
A venture platform with a large health portfolio and funds as well as single deals.
- VitaDAO
Token-governed funding of longevity research.
Report Appendix
Evidence & Methodology
19 cited passages on file; sources, scope, and how the review was assembled
+
Report Appendix
Evidence & Methodology
19 cited passages on file; sources, scope, and how the review was assembled
Evidence on file
19 supporting passages on file for Capital Cell and its offerings from 16 source documents, 9 discrepancies flagged. Each passage records the metric it supports, the value read from the document, the page, and the verbatim text where the document has it. Terminal subscribers read the passages; open them in the terminal.
- Cited passages
- 19
- Source documents
- 16
- Analyst verified
- 0
- Discrepancies flagged
- 9
ASReview Evidence
Methodology
Firecrawl captures of capitalcell.com (33 pages, all eight track-record pages parsed into 156 rounds, Spanish and English portfolio analyses, 2024 summary slides read as images); CNMV crowdfunding-provider register pages for provider no. 12; GLEIF; UK Companies House records for Capital Cell Ltd; web searches for sanctions and disputes. No account was opened.
Scope
PFP CAPITAL CELL, S.L. and the rounds on its public track record.
Key Findings
- *Portfolio analysis: 'the cash return as of November 2022 is only 0.51'.
- *Rendimiento de cartera: 'si eliminamos las 3 inversiones con mayor revalorización, el rendimiento de cartera pasa de X3,19 a únicamente X1,14'.
- *Investor FAQs: 'Capital Cell takes a small commission on the capital it helps raise - 7% per project'.
- *Conditions applicable to promoters: 'Cash Success Fee: An amount equivalent to 8% of the Commissionable Amount Raised, with a minimum of €10,000.'
- *How to invest: 'An 8% carried interest at the time of divestment.'
- *STAK page: 'A performance fee equivalent to 8% of the profit earned is charged.'
- *CNMV partners: 'CAPITAL CELL, LTD 100.00%'.
Primary Source Pages
FAQ
Frequently Asked Questions
High-intent search questions answered directly, without making users hunt through the full review.
What is Capital Cell?
A Barcelona-based equity crowdfunding platform for early-stage life-science companies, run by PFP CAPITAL CELL, S.L. and authorized by Spain's CNMV as a European crowdfunding service provider (no. 12). Investors buy shares, usually through a Dutch STAK, alongside a lead investor in each round.
Is Capital Cell legit?
It is licensed by the CNMV under the EU crowdfunding regulation, holds investor money at a payment institution until each round closes, publishes its full round list and a related-party ledger, and no sanction or dispute was located. The open question is ownership: the CNMV register still lists a UK parent that Companies House shows dissolved in 2025.
What returns has Capital Cell delivered?
Its analysis of the 2015 to 2022 portfolio reported a value of 3.19x invested capital on paper, 1.14x without its three best investments, and cash returned of 0.51 as of November 2022. The home page now shows 2.7x portfolio value. Four rounds at three companies are labelled exit (Vytrus Biotech, Goodgut and two Bionure rounds; Bionure merged into Accure Therapeutics in 2020); proceeds to investors are not published.
How many Capital Cell investments have failed?
Fourteen of 156 rounds are labelled 'Write-off' on the track record, EUR 8.0 million of round size; most rounds are from 2023 or later and too young to judge. Of the 39 rounds from 2016 to 2020, 8 are written off.
What fees does Capital Cell charge?
Published rates differ by page. Companies pay EUR 1,500 when the campaign page is activated and a cash success fee of 8% (EUR 10,000 minimum) per the promoter conditions and terms, though the investor FAQ says 7%. Investors holding through the STAK pay no annual fee, 8% of profit at exit (nothing if there is no profit) and 8% on transfers before an exit. The terms of each round govern.
What is the minimum investment?
Usually under EUR 1,000 and as low as about EUR 500. Under the EU regulation, non-sophisticated investors pass an entry knowledge test before full access, and investing more than the higher of EUR 1,000 or 5% of net worth in one project triggers a risk warning they must acknowledge.
Can US investors use Capital Cell?
Only as professional (accredited) investors, according to the FAQ; Capital Cell is not registered with the SEC. US persons should also check the tax treatment of a Dutch STAK certificate in a European company.
Can I sell my Capital Cell investment?
Through a bulletin board where registered users list shares and negotiate directly; direct shares are transferred before a notary, and STAK certificates carry an 8% transfer fee before exit.